Display options
Cite
Zhang L, Coombes J, Pascoe EM, et al. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016;21(1):14-23doi: 10.1179/1351000215Y.0000000022.
Zhang, L., Coombes, J., Pascoe, E. M., Badve, S. V., Dalziel, K., Cass, A., Clarke, P., Ferrari, P., McDonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M., Johnson, D. W., & On Behalf Of The Hero Study Collaborative Group. (2016). The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox report : communications in free radical research, 21(1), 14-23. https://doi.org/10.1179/1351000215Y.0000000022
Zhang, Lei, et al. "The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial." Redox report : communications in free radical research vol. 21,1 (2016): 14-23. doi: https://doi.org/10.1179/1351000215Y.0000000022
Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group. The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 04. PMID: 26083328; PMCID: PMC6837737.
Copy Download .nbib Format: NLM
Share it on

Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 04.

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.

Redox report : communications in free radical research

Lei Zhang, Jeff Coombes, Elaine M Pascoe, Sunil V Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P McDonald, Alicia T Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A Vergara, Carmel M Hawley, David W Johnson, On Behalf Of The Hero Study Collaborative Group

Affiliations

  1. a Australasian Kidney Trials Network, University of Queensland , Brisbane , Australia.
  2. b Department of Nephrology , Guangdong Provincial Hospital of Chinese Medicine , Guangzhou , China.
  3. c School of Human Movement Studies , University of Queensland , Brisbane , Australia.
  4. d Department of Nephrology , Princess Alexandra Hospital , Brisbane , Australia.
  5. e Center for Health Policy, Programs & Economics , University of Melbourne , Australia.
  6. f Menzies School of Health Research , Darwin , Australia.
  7. g Department of Renal Medicine , Fremantle Hospital , Australia.
  8. h Department of Nephrology and Transplantation Services , University of Adelaide at Central Northern Adelaide Renal and Transplantation Services , Australia.
  9. i Department of Nephrology , Royal Melbourne Hospital , Australia.
  10. j George Institute , Sydney , Australia.
  11. k Department of Renal Medicine , The Alfred Hospital , Melbourne , Australia.
  12. l Translational Research Institute , Brisbane , Australia.

PMID: 26083328 PMCID: PMC6837737 DOI: 10.1179/1351000215Y.0000000022

Abstract

OBJECTIVE: Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.

METHODS: This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.

RESULTS: Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD -6.06 U/l, P = 0.09), or protein carbonyls (MD -0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).

CONCLUSIONS: Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.

Keywords: Anaemia; Chronic kidney disease; Erythropoiesis-stimulating agent; Oxidative stress; Pentoxifylline

References

  1. Kidney Int. 2001 May;59(5):1960-6 - PubMed
  2. J Am Soc Nephrol. 2008 Mar;19(3):593-9 - PubMed
  3. Methods Enzymol. 1990;186:464-78 - PubMed
  4. Blood. 2004 Jul 1;104(1):43-50 - PubMed
  5. BMC Nephrol. 2008 Aug 01;9:8 - PubMed
  6. N Engl J Med. 2010 Sep 16;363(12):1146-55 - PubMed
  7. J Ren Nutr. 2007 Sep;17(5):296-304 - PubMed
  8. Anal Biochem. 1990 Feb 1;184(2):193-9 - PubMed
  9. Am J Kidney Dis. 2015 Jan;65(1):49-57 - PubMed
  10. J Formos Med Assoc. 2014 Jan;113(1):3-10 - PubMed
  11. Am J Kidney Dis. 2009 Dec;54(6):1089-97 - PubMed
  12. Nephrology (Carlton). 2004 Aug;9(4):223-8 - PubMed
  13. J Natl Med Assoc. 2009 Apr;101(4):336-44 - PubMed
  14. PLoS One. 2014 Jan 02;9(1):e84943 - PubMed
  15. Nephrol Dial Transplant. 2002;17 Suppl 11:39-43 - PubMed
  16. J Pharm Biomed Anal. 2014 Mar;90:161-6 - PubMed
  17. Am J Kidney Dis. 2007 Sep;50(3):471-530 - PubMed
  18. ASAIO J. 2001 Sep-Oct;47(5):516-21 - PubMed
  19. J Am Soc Nephrol. 2004 Jul;15(7):1877-82 - PubMed
  20. Nephrol Dial Transplant. 2003 Nov;18 Suppl 8:viii17-22 - PubMed
  21. Acta Biochim Pol. 2006;53(4):663-77 - PubMed
  22. Int Urol Nephrol. 2013 Apr;45(2):495-501 - PubMed
  23. Nephrol Dial Transplant. 2005 Sep;20 Suppl 8:viii2-7 - PubMed
  24. Nephron Clin Pract. 2010;116(4):c294-9 - PubMed
  25. Indian J Biochem Biophys. 1998 Jun;35(3):184-8 - PubMed
  26. Transplant Proc. 2007 Dec;39(10):3035-40 - PubMed
  27. Biomark Insights. 2008 May 27;3:419-428 - PubMed
  28. Clin Nephrol. 1999 Oct;52(4):239-45 - PubMed
  29. Kidney Int. 2004 Mar;65(3):1009-16 - PubMed
  30. Nephrol Dial Transplant. 2003 Jul;18(7):1272-80 - PubMed
  31. Saudi J Kidney Dis Transpl. 2014 Jan;25(1):73-8 - PubMed
  32. Biochem Res Int. 2013;2013:358985 - PubMed

Publication Types